ETFs Lineage Cell Therapeutics, Inc.

LCTX

US53566P1093

Biotechnology & Medical Research

Market Closed - NYSE 16:00:00 2026-09-28 EDT			5-day change	1st Jan Change
0.9710 ^USD	-5.73%		-5.73%	-41.86%

08-07	Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06	Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

ETFs positioned on Lineage Cell Therapeutics, Inc.

Name	YTD change	Weight	AuM
ISHARES BIOTECHNOLOGY ETF - USD	+24.85%	0.04%	9,953 M€
VANGUARD EXTENDED MARKET ETF - USD	+11.30%	0%	32,130 M€
STATE STREET SPDR RUSSELL 2000 U.S. SMALL CAP UCITS ETF - USD	+14.82%	0%	5,739 M€
LEUTHOLD CORE ETF - USD	+5.38%	0%	68 M€
VANGUARD MORNINGSTAR TOTAL STOCK MARKET ETF - USD	+12.10%	0%	692,025 M€
VANGUARD MORNINGSTAR U.S. TOTAL MARKET INDEX ETF - CAD	+15.86%	0%	14,144 M€
VANGUARD GROWTH ETF PORTFOLIO - CAD	+11.42%	0%	7,793 M€
UPAR ULTRA RISK PARITY ETF - USD	-2.65%	0%	59 M€
VANGUARD ALL-EQUITY ETF PORTFOLIO - CAD	+15.99%	0%	12,086 M€
ELM MARKET NAVIGATOR ETF - USD	+7.69%	0%	594 M€
VANGUARD CONSERVATIVE ETF PORTFOLIO - CAD	+3.98%	0%	688 M€
VANGUARD BALANCED ETF PORTFOLIO - CAD	+7.71%	0%	4,204 M€
DEFINED DURATION 20 ETF - USD	+11.51%	0%	19 M€
RPAR RISK PARITY ETF - USD	-0.42%	0%	580 M€
CAMBRIA TAX AWARE ETF - USD	+6.67%	0%	26 M€
VANGUARD CONSERVATIVE INCOME ETF PORTFOLIO - CAD	+0.33%	0%	184 M€
VANGUARD RETIREMENT INCOME ETF PORTFOLIO - CAD	+1.53%	0%	267 M€
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	+6.30%	0%	37 M€
ISHARES LIFEPATH TARGET DATE 2030 ETF - USD	+5.47%	0%	80 M€
CLEARSHARES OCIO ETF - DISTRIBUTING - USD	+9.34%	0%	176 M€
AB US EQUITY ETF - USD	+9.47%	0%	727 M€
CAMBRIA US EW ETF - USD	+9.44%	0%	194 M€
ALPHA ARCHITECT US EQUITY 2 ETF - USD	+11.51%	0%	513 M€
DEFINED DURATION 5 ETF - USD	-0.30%	0%	18 M€
CAMBRIA GLOBAL EW ETF - USD	+8.01%	0%	146 M€
CAMBRIA ENDOWMENT STYLE ETF - USD	+10.61%	0%	156 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+13.44%	-.--%	62 M€

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).

Employees

Sector

Biotechnology & Medical Research

More about the company